Abstract:Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Deregulated Wnt signaling has been implicated in a wide range of cancer types, both through truncating mutations in the tumor suppressor protein Adenomatous Polyposis Coli (APC), most prevalent in colorectal cancer, as well as overexpression of Wnt ligands and receptors. Canonical Wnt signaling involves the regulated degradation of the beta catenin protein. In the absence of Wnt signaling, cytosolic beta catenin levels are maintained at low levels, as a result of its phosphorylation-dependent ubiquitination and subsequent proteasomal degradation. This degradation is mediated by the ‘destruction complex’, whose constituents include Glycogen Synthase Kinase 3 (GSK3β), Casein Kinase 1 (CK1) and the scaffolding proteins Axin and APC. The efficient assembly of this complex depends upon the steady state levels of its components, such as Axin, which when overexpressed has been shown to decrease beta catenin levels and inhibit Wnt signaling. Recent reports suggest that the poly-ADP-ribosylating Tankyrase enzymes can bind to and regulate Axin levels, hence providing promising targets for treating Wnt-dependent tumors. We have identified potent, low nM small molecule inhibitors of the Wnt pathway, which inhibit Tankyrases 1 and 2, stabilize Axin, deplete beta catenin protein levels and modulate a set of Wnt-regulated genes in colorectal cell lines in a similar manner as seen when using siRNA to beta catenin. Furthermore, using siRNAs to Tankyrase 1 and 2 we have shown that co-depletion of both enzymes is required for Axin stabilization and Wnt pathway inhibition. We have also successfully demonstrated that our lead molecules cause prolonged Axin stabilization and Wnt pathway inhibition in vivo following oral BID dosing in colon xenografts carrying APC mutations. However, in contrast to previous reports, using molecular tools and our lead compounds (e.g. inducible Axin cell lines, compound rescue experiments using siRNAs to Axin 1/2), we have shown that Axin stabilization has no effect on the viability/proliferation of APC mutant colorectal cell lines, under conditions where siRNA to beta catenin was able to cause significant growth inhibition. Some potential mechanistic rationales for this lack of phenotypic effect will be presented. Understanding the consequences of Tankyrase inhibition in vivo in relevant disease models will be important to establish the clinical utility of these molecules in colorectal cancer and beyond. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5196. doi:10.1158/1538-7445.AM2011-5196

A small molecule compound 759 inhibits the wnt/beta-catenin signaling pathway via increasing the Axin protein stability

C644‐0303, a small‐molecule inhibitor of the Wnt/β‐catenin pathway, suppresses colorectal cancer growth

Direct Targeting of Β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling.

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Pharmacological targeting of Axin2 suppresses cell growth and metastasis in colorectal cancer

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Discovery Of An Orally Bioavailable Small-Molecule Inhibitor For The Beta-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction

Molecular docking-aided identification of small molecule inhibitors targeting β-catenin-TCF4 interaction

Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells

Increased Sensitivity To Wnt/Beta-Catenin Inhibitors In Hepatocellular Carcinoma Cells Harboring Activating Mutation Of Beta-Catenin

XAV939 inhibits the proliferation and migration of lung adenocarcinoma A549 cells through the WNT pathway

Discovery of 2-(isoxazol-5-yl)phenyl 3,4-dihydroxybenzoate as a potential inhibitor for the Wnt/β-catenin pathway

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Discovery of 2-(3-(3-carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives As Novel Small-Molecule Inhibitors of the Β-Catenin/b-cell Lymphoma 9 Protein–Protein Interaction

The Discovery Of Small Molecule Inhibitors Of Tankyrases 1 And 2, Which Modulate Axin Homeostasis And Inhibit Wnt Signaling In Vivo

Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer

Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α

Relationship Between Epithelial Cell Adhesion Molecule and Wingless/integrated-Β-catenin Signaling in Colon Cancer and the Effect of XAV939 on the Expression of Related Markers

Wnt Signaling Pathway Collapse upon β-Catenin Destruction by a Novel Antimicrobial Peptide SKACP003: Unveiling the Molecular Mechanism and Genetic Activities Using Breast Cancer Cell Lines

A Novel Imidazopyridine Derivative Exhibits Anticancer Activity in Breast Cancer by Inhibiting Wnt/β‐catenin Signaling

Inhibiting The Wnt Signaling Pathway With Small Molecules